Published “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial” in The Lancet Oncology — cited 4,419 times.
- #crossref
- #research
- #work